IDH1 and glioblastoma: Because GBM is known to have genetic heterogeneity [36], further studies with a larger study cohort may be needed for understanding how other tumor genetics beyond MGMT status may be related to IDH-wild-type GBM recurrence location, dose distributions, and change in morphological features after radiation therapy.